摘要
1型糖尿病(T1DM)是一种自身免疫性疾病,人们希望基于发病机制进行免疫干预治疗可以达到预防和逆转T1DM的目的。近30余年,免疫干预临床试验逐渐开展,包括免疫调节药物、调节性T细胞、干细胞治疗和胰岛移植等。尽管这些试验通过抑制自身免疫应答或胰岛B细胞替代,可以延缓胰岛B细胞功能的衰退或短期内脱离胰岛素治疗,但仍有各自的局限性。文章将结合最新的临床试验数据对免疫干预治疗T1DM的研究进展进行总结和展望。
Type 1 diabetes mellitus(T1DM)is an autoimmune disease. It is hoped that immune intervention based on pathogenesis can prevent and reverse T1DM. In the past 30 years,clinical trials of immune intervention have been conducted gradually,including immunoregulatory drugs,regulatory T cells,stem cell therapy and islet transplantation. Although these trials can delay the decline of islet function or be free from insulin-dependent therapy in a short term by inhibiting the autoimmune response or islet β cell replacement,they also have limitations. This article summarized the progress of immune intervention for T1DM based on the latest clinical trial data,and put forward prospects.
作者
何斌斌
周智广
HE Bin-bin;ZHOU Zhi-guang(Department of Metabolism and Endocrinology,the Second Xiangya Hospital,Central South University,Changsha 410011,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2020年第1期25-29,共5页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金青年科学基金（81600649）
